Text Size

Vascular Endothelial Growth Factor (VEGF) Levels in Brain Tumor Patients

This study has been withdrawn prior to enrollment.
Sponsor:
Collaborator:
Upper Michigan Brain Tumor Center
Information provided by (Responsible Party):
Richard A. Rovin, MD FACS, Marquette General Health System
ClinicalTrials.gov Identifier:
NCT00985036
First received: September 25, 2009
Last updated: April 20, 2012
Last verified: April 2012
History of Changes
  Purpose

Objectives: This study is looking at the level of vascular endothelial growth factor (VEGF) circulating in the blood stream of patients diagnosed with either a meningioma or a glioma. The questions that will be addressed include:

  1. Can VEGF level alert us to tumor progression or recurrence before MRI changes occur?
  2. Is the VEGF level an indicator of the response to treatment?
  3. Does the VEGF level correlate with tumor histology and behavior?
  4. Is there a relationship between VEGF level and outcome?

Condition Intervention
Glioma
Meningioma
 Procedure: Blood test

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Prospective
Official Title: Is VEGF a Useful Serum Biomarker for Patients Diagnosed With Meningioma or Glioma?

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by Marquette General Health System:

Primary Outcome Measures:
  • Determine if VEGF levels correlate with tumor progression or recurrence [ Time Frame: every one to three months ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Determine if the VEGF level is an indicator of the response to treatment. [ Time Frame: Every one to three months ] [ Designated as safety issue: No ]
  • Determine if the VEGF level correlates with tumor histology and behavior. [ Time Frame: Every one to three months ] [ Designated as safety issue: No ]
  • Determine if there is a relationship between VEGF level and outcome. [ Time Frame: Every one to three months ] [ Designated as safety issue: No ]

Biospecimen Retention:   Samples Without DNA

serum


Enrollment: 0
Study Start Date: September 2009
Estimated Study Completion Date: January 2012
Estimated Primary Completion Date: September 2011 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
Glioma
patients who are diagnosed with and are being treated for glioma
 Procedure: Blood test
an additional vial of blood will be obtained at the time of MRI or at the time of routine blood tests ordered by the medical oncologist. In other words, there will be no extra needle sticks. Just an extra vial of blood will be taken during a routine blood test
meningioma
patients who are diagnosed with and are being treated for meningioma
 Procedure: Blood test
an additional vial of blood will be obtained at the time of MRI or at the time of routine blood tests ordered by the medical oncologist. In other words, there will be no extra needle sticks. Just an extra vial of blood will be taken during a routine blood test

  Eligibility

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population

Patients presenting to Marquette General Hospital with a probable or confirmed diagnosis of meningioma or glioma

Criteria

Inclusion Criteria:

  • any patient presenting with glioma or meningioma

Exclusion Criteria:

  • a different type of brain tumor
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00985036

Locations
United States, Michigan
Marquette General Hospital
Marquette, Michigan, United States, 49855
Sponsors and Collaborators
Marquette General Health System
Upper Michigan Brain Tumor Center
Investigators
Principal Investigator: Richard A Rovin, MD, FACS Upper Michigan Brain Tumor Center
Principal Investigator: Robert J Winn, PhD Northern Michigan University
Principal Investigator: Suresh Nukala, MD Marquette General Health Systems
  More Information

No publications provided

Responsible Party: Richard A. Rovin, MD FACS, Neurosurgeon, Marquette General Health System
ClinicalTrials.gov Identifier: NCT00985036     History of Changes
Other Study ID Numbers: MGH-VEGF-1
Study First Received: September 25, 2009
Last Updated: April 20, 2012
Health Authority: United States: Institutional Review Board

Keywords provided by Marquette General Health System:
glioma
meningioma
VEGF

Additional relevant MeSH terms:
Glioma
Meningioma
Neoplasms, Neuroepithelial
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue
Neoplasms, Vascular Tissue
 Meningeal Neoplasms
Central Nervous System Neoplasms
Nervous System Neoplasms
Neoplasms by Site
Nervous System Diseases
Endothelial Growth Factors
Growth Substances
Physiological Effects of Drugs
Pharmacologic Actions

ClinicalTrials.gov processed this record on May 16, 2013